Premium
THE EFFECT OF “PARENABOL” ON PATIENTS WITH OSTEOPOROSIS
Author(s) -
Melick R. A.,
Baird C. W.
Publication year - 1970
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1970.tb63287.x
Subject(s) - osteoporosis , medicine , excretion , cirrhosis , urinary system , side effect (computer science) , gastroenterology , surgery , computer science , programming language
“Parenabol” (3 oxo delta 1–4 – androstadiene – 17 beta – ol undecylenate) was given intramuscularly every two weeks for two to six months to 20 patients with osteoporosis. The dose per injection was either 50 mg (nine patients) or 25 mg (11 patients). Most patients described subjective improvement. Although no patient was malnourished and hæmoglobin levels were normal before treatment, there was a rise in the hæmoglobin level in the group receiving the 50 mg dosage, and in the serum protein content in the group receiving 25 mg. Neither dosage lowered the urinary excretion of calcium, and in one case osteoporosis progressed during treatment. One patient with alcoholic cirrhosis developed gynæcomastia after starting “Parenabol”. There were no other side effects, though BSP retention increased in three cases.